Overview

Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis

Status:
Terminated
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
THE STUDY HAS BEEN DESIGNED TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS
Phase:
Phase 2
Details
Lead Sponsor:
Alfa Wassermann S.p.A.
Alfasigma S.p.A.
Collaborator:
Parexel
Treatments:
Metronidazole
Rifamycins
Rifaximin